The Biopharmaceutical Market Worldwide Will Be Worth Nearly One Trillion USD by 2030 The Global Biopharmaceutical Market is anticipated to be valued at almost $1 trillion USD by 2030 (As stated by Statista 2023). As chronic diseases like cancer, diabetes, and heart disease are becoming more prevalent around the world, there is a surge in...
The biopharma industry has witnessed extensive growth in recent years due to the rising demand for drugs to treat and cure a wide range of diseases. The biopharma industry is changing how we identify and treat diseases thanks to developments in gene editing, biosensors, and other technologies. However, with this growth comes a plethora of...
IMAPAC has a new comprehensive market intelligence tool to produce pharma and pharmaceutical market data in real-time. The visualization tool makes it possible to analyze historical and current data in real time in a matter of seconds instead of many hours. Apart from scalability, the data tool opens a spectrum of new analytical and reporting...
With the increasing complexity of products, competition, regulations, and global markets, the need for comprehensive market intelligence has become increasingly essential in order to remain successful in the most rapidly expanding industry- Biopharmaceuticals. For biopharma companies, market research services are proving to be a valuable asset in product development. Companies conduct market research in pharmaceutical...
Excerpt Medigen Vaccine Biologics Corp (高端疫苗) has applied to the Australian medicines regulator for provisional approval of its COVID-19 vaccine. Article Summary Medigen Vaccine Biologics Corp applied to Australian medicines regulator for provisional approval of the COVID-19 vaccine and has delivered the necessary documents to the Australian Therapeutic Goods Administration (TGA), but did not say...
Excerpt Prestige Biopharma Limited, announced that its first-in-class antibody PBP1510 has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’ and was placed on the INN Recommended List by the World Health Organization (WHO). Article Summary Prestige Biopharma Limited first-in-class antibody has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’. INN-Ulenistamab, which is also known as...
Excerpt WuXi Biologics launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. Article Summary Wuxi Biologics, a global CRDMO service company, recently opened its DP5 facility in Wuxi, China. The facility is the ninth active facility in WuXi Biologics’ global network. A continuous and steady isolator filling system...
Astellas Pharma Inc has announced the opening of a new late stage clinical and commercial manufacturing facility in Sanford, North Carolina, US. The facility will allow the company to expand its resources and team to establish a robust, global supply chain and expand its therapeutic and geographic scope. Article Summary The new 135,000 square-foot state-of-the-art...
The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs has accelerated the plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer. Article Summary Planning has begun on a massive...
A clinical-stage oncology company Prescient Therapeutics (PTX) has launched its second cell therapy platform, CellPryme-M, which produces superior cells with greater cancer killing activity. This platform opens commercial opportunities for the company to incorporate it into third-party manufacturing processes. Article Summary PTX has developed this new platform technology in association with its research partner, Peter...
